Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer.

Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G.

Breast. 2014 Feb;23(1):69-75. doi: 10.1016/j.breast.2013.11.007. Epub 2013 Dec 4.

PMID:
24314620
[PubMed - in process]
2.

Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer.

Sutepvarnon A, Warnnissorn M, Srimuninnimit V.

J Med Assoc Thai. 2013 Feb;96 Suppl 2:S60-6.

PMID:
23590023
[PubMed - indexed for MEDLINE]
3.
4.

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.

Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M, Lagarde N, Martin AL, Asselain B, Roché H.

J Clin Oncol. 2009 Jun 10;27(17):2809-15. doi: 10.1200/JCO.2008.18.2808. Epub 2009 Apr 20.

PMID:
19380452
[PubMed - indexed for MEDLINE]
5.

Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.

Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA.

PLoS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946. Epub 2012 Jun 5.

PMID:
22679488
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.

International Breast Cancer Study Group (IBCSG).

J Natl Cancer Inst. 2002 Jul 17;94(14):1054-65. Erratum in: J Natl Cancer Inst 2002 Sep 4;94(17):1339.

PMID:
12122096
[PubMed - indexed for MEDLINE]
Free Article
7.

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. doi: 10.1093/jnci/djp082. Epub 2009 May 12.

PMID:
19436038
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.

Jacquemier J, Boher JM, Roche H, Esterni B, Serin D, Kerbrat P, Andre F, Finetti P, Charafe-Jauffret E, Martin AL, Campone M, Viens P, Birnbaum D, Penault-Llorca F, Bertucci F.

Breast Cancer Res. 2011;13(6):R109. doi: 10.1186/bcr3051. Epub 2011 Nov 1.

PMID:
22044691
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.

Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.

Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8.

PMID:
21901395
[PubMed - indexed for MEDLINE]
10.

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C.

J Clin Oncol. 2009 Mar 10;27(8):1168-76. doi: 10.1200/JCO.2008.18.1024. Epub 2009 Feb 9.

PMID:
19204205
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
[PubMed - indexed for MEDLINE]
12.

Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.

Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B.

Acta Oncol. 2013 Jan;52(1):91-101. doi: 10.3109/0284186X.2012.713508. Epub 2012 Aug 30.

PMID:
22934555
[PubMed - indexed for MEDLINE]
13.

Prognostic importance of thymidylate synthase expression in early breast cancer.

Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortés-Funes H, Simmoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Allegra CJ, Johnston PG.

J Clin Oncol. 1997 May;15(5):1923-31.

PMID:
9164203
[PubMed - indexed for MEDLINE]
14.

The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.

Fowble B, Fein DA, Hanlon AL, Eisenberg BL, Hoffman JP, Sigurdson ER, Daly MB, Goldstein LJ.

Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):669-77.

PMID:
8690632
[PubMed - indexed for MEDLINE]
15.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
16.

BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.

Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechère L, Reed JC.

Clin Cancer Res. 2010 Aug 1;16(15):3988-97. doi: 10.1158/1078-0432.CCR-10-0079. Epub 2010 Jun 24.

PMID:
20576719
[PubMed - indexed for MEDLINE]
Free Article
17.

One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.

Ejlertsen B, Jensen MB, Elversang J, Rasmussen BB, Andersson M, Andersen J, Nielsen DL, Cold S, Mouridsen HT.

Eur J Cancer. 2013 Sep;49(14):2986-94. doi: 10.1016/j.ejca.2013.05.006. Epub 2013 Jun 8.

PMID:
23756360
[PubMed - indexed for MEDLINE]
18.

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, Coates AS, Gusterson BA.

J Clin Oncol. 2010 Jun 20;28(18):2966-73. doi: 10.1200/JCO.2009.25.9549. Epub 2010 May 10.

PMID:
20458051
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.

Hayashi N, Niikura N, Yamauchi H, Nakamura S, Ueno NT.

Breast Cancer Res Treat. 2013 Jan;137(2):523-31. doi: 10.1007/s10549-012-2336-6. Epub 2012 Nov 27.

PMID:
23184079
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54. doi: 10.1007/s00432-008-0414-2. Epub 2008 May 17.

PMID:
18488249
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk